Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan.
We retrospectively analyzed the clinical outcome of chronic myelogenous leukemia (CML) patients who received imatinib mesylate (IM) as initial therapy at Tokyo University Hospital. In all patients, molecular response as well as hematological and cytogenetic response was measured routinely. Our cohort showed respectable outcome with complete cytogenetic response (CR) of 82% in 1 year, and 97% in 5 years. The estimated progression free survival of 29 patients who were in chronic phase at diagnosis was 97% and the estimated OS was 92.4% at 5 years. Although IM interruption due to side effects was observed in about half of the cases, the discontinuation was only temporary in all cases. However, patients who showed persistent intolerance with adequate dose of IM (300 mg/day or more) showed poor molecular response.
Nannya
Yasuhito
Y
Department of Hematology and Oncology, Graduate School of Medicine, Tokyo University, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Yokota
Hiromitsu
H
Department of Clinical Laboratory Medicine, Graduate School of Medicine, Tokyo University, Tokyo, Japan.
Sato
Yumiko
Y
Department of Clinical Laboratory Medicine, Graduate School of Medicine, Tokyo University, Tokyo, Japan.
Yamamoto
Go
G
Department of Hematology and Oncology, Graduate School of Medicine, Tokyo University, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Asai
Takashi
T
Department of Hematology and Oncology, Graduate School of Medicine, Tokyo University, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Ichikawa
Motoshi
M
Department of Hematology and Oncology, Graduate School of Medicine, Tokyo University, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Watanabe
Takuro
T
Department of Hematology and Oncology, Graduate School of Medicine, Tokyo University, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Kumano
Keiki
K
Department of Hematology and Oncology, Graduate School of Medicine, Tokyo University, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.|Department of Cell Therapy and Transplantation, Graduate School of Medicine, Tokyo University, Tokyo, Japan.
Hangaishi
Akira
A
Department of Hematology and Oncology, Graduate School of Medicine, Tokyo University, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Takahashi
Tsuyoshi
T
Department of Hematology and Oncology, Graduate School of Medicine, Tokyo University, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Chiba
Shigeru
S
Department of Cell Therapy and Transplantation, Graduate School of Medicine, Tokyo University, Tokyo, Japan.
Yatomi
Yutaka
Y
Department of Clinical Laboratory Medicine, Graduate School of Medicine, Tokyo University, Tokyo, Japan.
Kurokawa
Mineo
M
Department of Hematology and Oncology, Graduate School of Medicine, Tokyo University, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. kurokawa-tky@umin.ac.jp.|Department of Cell Therapy and Transplantation, Graduate School of Medicine, Tokyo University, Tokyo, Japan. kurokawa-tky@umin.ac.jp.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D007564:Japan; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl